Skip to content

Mindfulness Meditation for Insomnia

Neurophysiological Patterns of Mindfulness Meditation for Insomnia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04242771
Enrollment
13
Registered
2020-01-27
Start date
2022-12-02
Completion date
2023-08-01
Last updated
2024-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insomnia

Brief summary

This is a pilot study evaluating the feasibility and acceptability of a non-pharmacological, mind-body intervention to improve sleep quality, including a preliminary evaluation of neurophysiological signals. The study involves 4 weeks of guided mind-body practice at home using a smartphone app during bedtime and pre/post in-lab sleep study visits.

Interventions

BEHAVIORALMindfulness

Subjects practice mindfulness before bedtime

Sponsors

Beth Israel Deaconess Medical Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* 1\. age 20 - 50 years\* * 2\. chronic insomnia (defined by Diagnostic and Statistical Manual Diploma in Social Medicine, DSM-V or International Classification of Sleep Disorders - Third Edition, ICSD-3) with sleep latency \>20 minutes * 3\. speak and understand English * 4\. have a smart phone for mobile app installation

Exclusion criteria

* 1\. sleep disorders other than insomnia (e.g., narcolepsy, restless leg syndrome, sleep deprivation, jet lag, etc) * 2\. shift worker or routine night shifts * 3\. women with pregnancy or breast feeding * 4\. history of head trauma or surgery * 5\. regular (defined as twice a week or more) practice of mind-body interventions * 6\. neurological disorders (e.g. epilepsy, dementia, stroke, Parkinson's disease, neuroinfections, brain tumors, etc.) * 7\. current use of neurologic, psychiatric, or cardiovascular medications that have expected neuropsychiatric or cardiovascular effects (i.e., beta-blockers, hypnotics, antidepressants).

Design outcomes

Primary

MeasureTime frameDescription
Feasibility (i.e., subject retention at initial follow-up assessment)At one month follow up visitThe primary metric for assessing Feasibility will be subject retention at the initial follow-up assessment. This includes the proportion of enrolled subjects that are active in the study at the initial follow-up assessment.

Secondary

MeasureTime frameDescription
AcceptabilityAt completion of the 4 week programThe primary metric for assessing Acceptability will be a self-report Acceptability questionnaire which evaluates enjoyableness, convenience, helpfulness, relevancy, odds of future use, and overall satisfaction of the program.

Other

MeasureTime frameDescription
Insomnia Severity IndexAt baseline and at the end of 4-week programA commonly used subjective sleep measure
Polysomnogram-derived sleep onset latencyAt baseline and at the end of 4-week programThe amount of time it takes to fall asleep after the lights have been turned off.
Polysomnogram-derived sleep efficiencyAt baseline and at the end of 4-week programSleep efficiency is the ratio of the total time spent asleep (total sleep time) in a night compared to the total amount of time spent in bed.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026